Typhoid Conjugate Vaccine is indicated for active immunization against infections caused by Salmonella typhi in infants, children, adolescents, and adults aged over 6 months up to 45 years.

Typhoid Vi Conjugate Vaccine is a clear, colorless solution that is free from visible particles. It contains 25 mcg of Typhoid Vi polysaccharide conjugated to CRM₁₉₇. The polysaccharide is produced from Citrobacter freundii sensu lato 3056 (Vi) and linked to CRM₁₉₇ as a carrier protein. Sodium chloride and phosphate buffer are included as diluents (buffering agents) in the formulation, while 2-phenoxyethanol is used as a preservative. BE’s Typhoid Vi Conjugate Vaccine is administered as a single 0.5 mL intramuscular dose to infants, children, adolescents, and adults aged over 6 months up to 45 years. The vaccine complies with I.P. and WHO standards.

A single 0.5 mL dose should be administered intramuscularly in the deltoid muscle of the upper arm for children aged 2 years and above, adolescents, and adults, provided adequate muscle mass is present. For infants and toddlers aged over 6 months to under 2 years, the vaccine should be given intramuscularly in the vastus lateralis muscle on the anterolateral aspect of the thigh. The vaccine should not be injected into the gluteal region or into areas where major nerves are present.

Currently, there is no clinical evidence regarding the co-administration of this vaccine with other products. Therefore, Biological E’s Typhoid Vi Conjugate Vaccine should not be mixed with any other vaccine or medicinal product. If given simultaneously with other vaccines, separate syringes and different injection sites should be used.

• Hypersensitivity to any component of the vaccine
• Pregnant and breastfeeding women
• Presence of fever or severe infection

The most commonly reported local adverse reactions following administration of Biological E’s Typhoid Vi Conjugate Vaccine include injection site pain (4.50%), redness (0.64%), and swelling (0.32%). These reactions typically occur within the first 48 hours and resolve within 2–3 days. Common systemic adverse reactions include fever (2.25%), vomiting (0.96%), headache (0.64%), fatigue (0.64%), joint pain (0.32%), and rash (0.32%). No serious vaccine-related adverse events were reported in clinical trials.

The safety and effectiveness of this vaccine have not been established in pregnant or breastfeeding women. It is not known whether the vaccine is excreted in human milk.

Do not administer this vaccine intravenously, intradermally, or subcutaneously. Typhoid conjugate vaccine provides protection against typhoid fever caused by Salmonella typhi, but it does not protect against Salmonella paratyphi or other non-typhoidal Salmonella species.

Adrenaline (epinephrine) injection 1:1000 (1 mg/mL) should be readily available in case of severe allergic or anaphylactic reactions. After vaccination, the patient should be observed under medical supervision for at least 30 minutes. As with all vaccines, appropriate medical facilities and treatment should be available to manage any anaphylactic reactions.

Vaccines, Anti-sera & Immunoglobulin

Store the vaccine at 2°C to 8°C. Do not freeze—discard if frozen. Shake well before use and keep out of reach of children.